PANTHER
Phase 3 Completed
454 enrolled 41 charts
Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)
Phase 2 Completed
185 enrolled 12 charts
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
Phase 1 Completed
38 enrolled 14 charts
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
Phase 2 Completed
150 enrolled 17 charts
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Phase 1 Completed
241 enrolled
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
Phase 2 Completed
21 enrolled 14 charts
Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1 Completed
12 enrolled 16 charts
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1/2 Completed
73 enrolled 12 charts
APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
Phase 2 Completed
33 enrolled 7 charts
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 2/3 Completed
76 enrolled 16 charts
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 2 Completed
155 enrolled 24 charts
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Phase 1 Completed
17 enrolled 33 charts
Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486
Phase 2 Completed
40 enrolled
Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
Phase 1/2 Completed
28 enrolled 8 charts
ICT-HCT
Phase 2 Completed
50 enrolled 12 charts
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
Phase 3 Completed
14 enrolled 11 charts
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
Phase 1 Completed
94 enrolled
A Study of Pevonedistat in Adult East Asian Participants
Phase 1 Completed
23 enrolled 23 charts
Pharmacokinetics, Tolerability and Safety of NEX-18a
Phase 1 Completed
2 enrolled
Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat
Phase 2 Completed
14 enrolled
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
Phase 2 Completed
5 enrolled 9 charts
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
Phase 2 Completed
213 enrolled 35 charts
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1 Completed
43 enrolled
Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS
Phase 2 Completed
25 enrolled 13 charts
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
Phase 2 Completed
120 enrolled 39 charts
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase 2 Completed
68 enrolled 11 charts
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
Phase 1/2 Completed
55 enrolled 15 charts
RELAZA2
Phase 2 Completed
93 enrolled
Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR
Phase 2 Completed
40 enrolled 21 charts
TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid
Phase 2 Completed
12 enrolled
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
Phase 1/2 Completed
45 enrolled
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
Phase 2 Completed
24 enrolled 8 charts
Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk
Phase 2 Completed
113 enrolled 10 charts
AZACTA
Phase 1 Completed
5 enrolled
Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
Phase 2 Completed
17 enrolled 12 charts
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
Phase 1/2 Completed
113 enrolled 21 charts
AZALENA
Phase 2 Completed
50 enrolled
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Phase 1 Completed
89 enrolled
Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)
Phase 1 Completed
3 enrolled
Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)
Phase 3 Completed
187 enrolled 9 charts
Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.
Phase 2 Completed
50 enrolled
Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)
Phase 4 Completed
44 enrolled 26 charts
CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Phase 1 Completed
20 enrolled
RACE
Phase 1 Completed
31 enrolled
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies
Phase 1 Completed
63 enrolled
MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Phase 1 Completed
63 enrolled
Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)
Phase 2 Completed
28 enrolled 1 FDA
PKC412 and 5-Azacytidine
Phase 1/2 Completed
54 enrolled 8 charts
Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes
Phase 1/2 Completed
37 enrolled 14 charts
Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Phase 1 Completed
5 enrolled 9 charts